Page last updated: 2024-12-09

3-(3-methyl-2-thienyl)acrylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(3-methyl-2-thienyl)acrylic acid: residue of morantel found in bovine milk; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1485238
CHEMBL ID1651770
SCHEMBL ID5283644
MeSH IDM0144102

Synonyms (40)

Synonym
AC-12830
77741-66-3
STK504555
smr000369069
MLS001002546
(2e)-3-(3-methylthiophen-2-yl)prop-2-enoic acid
HMS1367A05
cp 20107
AKOS000263508
3-(3-methylthiophen-2-yl)prop-2-enoic acid
(e)-3-(3-methylthiophen-2-yl)prop-2-enoic acid
CHEMBL1651770
NCGC00246104-01
HMS2723M04
3-(3-methyl-2-thienyl)-2-propenoic acid
3-(3-methyl-2-thienyl)acrylic acid
2-propenoic acid, 3-(3-methyl-2-thienyl)-
cp-20,107
2-propenoic acid, 3-(3-methyl-2-thienyl)-, (2e)-
102696-70-8
7R-0651
85623dmp6i ,
unii-85623dmp6i
(2e)-3-(3-methyl-2-thienyl)acrylic acid
3-(3-methylthiophen-2-yl)acrylic acid
(e)-3-(3-methyl-2-thienyl)-2-propenoic acid
SCHEMBL5283644
J-501892
F9995-2610
(e)-3-(3-methylthiophen-2-yl)acrylic acid
(2e)-3-(3-methyl-2-thienyl)-2-propenoic acid #
3-(3-methylthiophen-2-yl)acrylicacid
Q27269598
A865165
3-(3-methyl-2-thienyl)acrylicacid
EN300-11219
CEA69670
CS-0368953
Z2942851704
EN300-832912
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID567047DPPH radical scavenging activity assessed as reducing ability at 0.2 mM after 20 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567040Antioxidant activity assessed as Fe3+/ascorbic acid-induced hydroxyl radical scavenging activity at 0.01 mM2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567048DPPH radical scavenging activity assessed as reducing ability at 0.2 mM after 60 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567042Antioxidant activity assessed as Fe3+/ascorbic acid-induced superoxide anion radical scavenging activity at 0.1 mM2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567038Inhibition of soybean LOX2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567041Antioxidant activity assessed as Fe3+/ascorbic acid-induced hydroxyl radical scavenging activity at 0.1 mM2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567045DPPH radical scavenging activity assessed as reducing ability at 0.1 mM after 20 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567050Antioxidant activity assessed as reduction of ABTS radical at 0.1 mM2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567046DPPH radical scavenging activity assessed as reducing ability at 0.1 mM after 60 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567051Antioxidant activity assessed as inhibition of linoleic acid peroxidation at 0.1 mM by AAPH assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567043DPPH radical scavenging activity assessed as reducing ability at 0.05 mM after 20 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567037Antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw oedema at 0.01 mmol/kg, ip2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567049Antioxidant activity assessed as inhibition of heme protein-dependent lipid peroxidation at 1 mM2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID567039Inhibition of COX1 at 100 uM2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.22 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]